drugset / Trial / NCT05972473
A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD
RandomizedParallel-groupTriple-blindTreatment
Summary
The study is designed for multi-center,randomized,double-masked,active-contralled study to evaluate effective and security of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.
Timeline
- Start
- 2023-09-21
- Primary completion
- 2027-02-28
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | IBI302 | Unknown | 8 mg | Intravitreal |